The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Extrahepatic Platelet-Derived Growth Factor-β, Delivered by Platelets, Promotes Activation of Hepatic Stellate Cells and Biliary Fibrosis in Mice
Open accessAbstract
Background & aims Platelet-derived growth factor-β (PDGFB) is a mitogen for hepatic stellate cells (HSCs). We studied the cellular sources of PDGFB and the effects of a high-affinity monoclonal antibody against PDGFB (MOR8457) in mouse models of biliary fibrosis.Methods Cellular sources of PDGFB were identified using quantitative reverse-transcription polymerase chain reaction, biochemical, and immunohistologic methods. Mice with advanced biliary fibrosis, MDR2(Abcb4)-null mice, and C57Bl/6 (control) mice were placed on 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-supplemented diets and were given weekly intraperitoneal injections of MOR8457. Platelets were depleted from MDR2-null mice by injection of an antibody against CD41, or inhibited with diets containing low-dose aspirin. Liver tissues were collected and analyzed by quantitative reverse-transcription PCR and histologic and biochemical analyses.Results Levels of PDGFB protein, but not messenger RNA, were increased in fibrotic livers of MDR2-null mice, compared with control mice. Platelet clusters were detected in the hepatic endothelium, in close proximity to HSCs, and were identified as a source of PDGFB protein in MDR2-null mice. Levels of the PDGFB were increased in serum samples from patients with early stages of liver fibrosis of various etiologies (F1-2, n = 16; P < .05), compared with nonfibrotic liver tissue (F0, n = 12). Depletion of platelets from MDR2-null mice normalized hepatic levels of PDGFB within 48 hours, reducing levels of a marker of HSC activation (α-smooth muscle actin) and expression of genes that promote fibrosis. Diets supplemented with low-dose aspirin reduced circulating serum and hepatic levels of PDGFB and significantly reduced progression of fibrosis in MDR2-null mice over 1 year. MOR8457 produced a dose-dependent decrease in liver fibrosis in MDR2-null mice, reducing collagen deposition by 45% and expression of fibrosis-associated genes by 50%, compared with mice given a control antibody. In vitro, platelets activated freshly isolated HSCs (induction of α-smooth muscle actin and fibrosis-associated genes) via a PDGFB-dependent mechanism. MOR8457 also reduced liver fibrosis in mice placed on DDC-supplemented diets.Conclusions Platelets produce PDGFB to activate HSC and promote fibrosis in MDR2-null mice and mice on DDC-supplemented diets. Antiplatelet therapy or selective inhibition of PDGFB might reduce biliary fibrosis in patients with liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NASH, platelets interact with liver-resident KCs to promote the recruitment of CD8 T cells and NKT cells, depending on interactions between platelet-expressed GPIba and von Willebrand factor, thereby promoting disease.98”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,687
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., Rodríguez, L. A. G., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,223
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Primary Sclerosing Cholangitis
Lee, Y., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 541
Primary sclerosing cholangitis
Lawson, A. (2014) · Radiopaedia.org · doi:10.53347/rid-26818 · Cited by 446
A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis
Fickert, P., Stöger, U., Fuchsbichler, A., Moustafa, T., Marschall, H., Weiglein, A. H., Tsybrovskyy, O., Jaeschke, H., Zatloukal, K., Denk, H., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061133 · Cited by 375
Sitia, G., Aiolfi, R., Lucia, P. D., Mainetti, M., Fiocchi, A., Mingozzi, F., Esposito, A., Ruggeri, Z., Chisari, F., Iannacone, M., et al. (2012) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1209182109 · Cited by 318
Popov, Y. V., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 297
Self-citationPopov, Y. V., Patsenker, E., Fickert, P., Trauner, M. A., & Schuppan, D. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.025 · Cited by 268
Self-citation
Cited by
Sorted by citations
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
Self-citationMechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
The good and the bad collagens of fibrosis – Their role in signaling and organ function
Karsdal, M. A., Nielsen, S. H., Leeming, D. J., Langholm, L. L., Nielsen, M. J., Manon-Jensen, T., Siebuhr, A., Gudmann, N. S., Rønnow, S., Sand, J. M., et al. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.014 · Cited by 509
Self-citationTGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1
Su, J., Morgani, S. M., David, C. J., Wang, Q., Er, E. E., Huang, Y.-H., Basnet, H., Zou, Y., Shu, W., Soni, R. K., et al. (2020) · Nature · doi:10.1038/s41586-019-1897-5 · Cited by 503
An, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V. (2020) · Nature Communications · doi:10.1038/s41467-020-16092-0 · Cited by 319
Self-citationIkenaga, N., Peng, Z., Vaid, K. A., Liu, S. B., Yoshida, S., Sverdlov, D., Mikels, A. J., Smith, V., Schuppan, D., & Popov, Y. V. (2017) · Gut · doi:10.1136/gutjnl-2016-312473 · Cited by 305
Self-citationPathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 291
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 288
Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation
Mandel, J., Casari, M., Stepanyan, M. G., Martyanov, A. A., & Deppermann, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073868 · Cited by 288
Klinkhammer, B. M., Floege, J., & Boor, P. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.008 · Cited by 238
Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.061 · Cited by 180
The PDGF system and its antagonists in liver fibrosis
Borkham‐Kamphorst, E., & Weiskirchen, R. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.10.002 · Cited by 187
Nallagangula, K. S., Nagaraj, S. K., Lakshmaiah, V., & Chandrappa, M. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0083 · Cited by 175
Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy
Cai, X., Wang, J., Wang, J., Zhou, Q., Yang, B., He, Q., & Weng, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104720 · Cited by 170
Platelets: No longer bystanders in liver disease
Chauhan, A., Adams, D., Watson, S. P., & Lalor, P. F. (2016) · Hepatology · doi:10.1002/hep.28526 · Cited by 138
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
Lange, N. F., Radu, P., & Dufour, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.025 · Cited by 144
Biology of portal hypertension
McConnell, M. J., & Iwakiri, Y. (2017) · Hepatology International · doi:10.1007/s12072-017-9826-x · Cited by 123
Peng, Z., Ikenaga, N., Liu, S. B., Sverdlov, D. Y., Vaid, K. A., Dixit, R., Weinreb, P. H., Violette, S., Sheppard, D., Schuppan, D., et al. (2016) · Hepatology · doi:10.1002/hep.28274 · Cited by 118
Self-citationUnderstanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Lee, M., Chung, G. E., Lee, J., Oh, S., Nam, J. Y., Chang, Y. W., Cho, H., Ahn, H., Cho, Y. Y., Yoo, J., et al. (2017) · Hepatology · doi:10.1002/hep.29318 · Cited by 116
Self-citationAspirin use is associated with lower indices of liver fibrosis among adults in the United States
Jiang, Z. G., Feldbrügge, L., Tapper, E. B., Popov, Y. V., Ghaziani, T., Afdhal, N. H., Robson, S. C., & Mukamal, K. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13515 · Cited by 106
Self-citationAngiodiversity and organotypic functions of sinusoidal endothelial cells
Reiners-Koch, P.-S., Lee, K. H., Goerdt, S., & Augustin, H. G. (2021) · Angiogenesis · doi:10.1007/s10456-021-09780-y · Cited by 101
Platelets as Key Factors in Hepatocellular Carcinoma
Pavlovic, N., Rani, B., Gerwins, P., & Heindryckx, F. (2019) · Cancers · doi:10.3390/cancers11071022 · Cited by 97
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Simon, T. G., Wilechansky, R. M., Stoyanova, S., Grossman, A., Dichtel, L. E., Lauer, G. M., Miller, K. K., Hoshida, Y., Corey, K. E., Loomba, R. S., et al. (2024) · JAMA · doi:10.1001/jama.2024.1215 · Cited by 96
Wan, Y., Meng, F., Wu, N., Zhou, T., Venter, J. K., Francis, H., Kennedy, L. L., Glaser, T., Bernuzzi, F., Invernizzi, P., et al. (2017) · Hepatology · doi:10.1002/hep.29138 · Cited by 91
Platelets in chronic liver disease, from bench to bedside
Ramadori, P., Klag, T., Malek, N. P., & Heikenwälder, M. F. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.001 · Cited by 88
Role of the blood coagulation cascade in hepatic fibrosis
Pant, A., Kopec, A. K., & Luyendyk, J. P. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00402.2017 · Cited by 87
Optimized Mouse Models for Liver Fibrosis
Kim, Y. O., Popov, Y. V., & Schuppan, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6786-5_19 · Cited by 84
Self-citationImmunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
“Accumulating studies suggest that aspirin exerts anti-in fl ammatory and antitumor effects by inhibiting cyclooxygenase-2 and platelet-derived growth factor signaling, representing a promising and low-cost strategy for the treatment of MASLD [207 – 209].”
Antifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. Z. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 76
Self-citationPlatelets as Modulators of Liver Diseases
Luyendyk, J. P., & Lisman, T. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1604091 · Cited by 73
Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis
Yang, F., Li, H., Li, Y., Hao, Y., Wang, C., Jia, P. P., Chen, X., Ma, S., & Xiao, Z. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108051 · Cited by 72
Torok, N. J., Dranoff, J. A., Schuppan, D., & Friedman, S. L. (2015) · Hepatology · doi:10.1002/hep.27720 · Cited by 71
Self-citationBallerini, P., Contursi, A., Bruno, A., Mucci, M., Tacconelli, S., & Patrignani, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838079 · Cited by 71
Wang, X., Wu, X., Zhang, A., Wang, S., Hu, C., Chen, W., Shen, Y., Tan, R. X., Sun, Y., & Xu, Q. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.042 · Cited by 65
SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles
Leber, N., Kaps, L., Aslam, M., Schupp, J., Brose, A., Schaeffel, D., Fischer, K., Diken, M., Strand, D. J., Koynov, K., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.006 · Cited by 63
Self-citationTherapeutic pro-fibrogenic signaling pathways in fibroblasts
Cannito, S., Novo, E., & Parola, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.017 · Cited by 60
NAFLD-Associated HCC: Progress and Opportunities
Geh, D., Anstee, Q. M., & Reeves, H. L. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s272213 · Cited by 64
Miyashita, T., Nakanuma, S., Ahmed, A. K., Makino, I., Hayashi, H., Oyama, K., Nakagawara, H., Tajima, H., Takamura, H., Ninomiya, I., et al. (2015) · European surgery. Supplement/European surgery · doi:10.1007/s10353-015-0363-3 · Cited by 57
Coagulation‐driven platelet activation reduces cholestatic liver injury and fibrosis in mice
Joshi, N., Kopec, A. K., O'Brien, K. M., Towery, K., Cline-Fedewa, H. M., Williams, K. J., Copple, B. L., Flick, M. J., & Luyendyk, J. P. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12770 · Cited by 55
The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver
Klindt, C., Reich, M., Hellwig, B., Stindt, J., Rahnenführer, J., Hengstler, J. G., Köhrer, K., Schoonjans, K., Häussinger, D., & Keitel, V. (2019) · Cells · doi:10.3390/cells8111467 · Cited by 55
Macrophages and platelets in liver fibrosis and hepatocellular carcinoma
Casari, M., Siegl, D., Deppermann, C., & Schuppan, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277808 · Cited by 55
Self-citationTreatment of Hepatic Fibrosis in Mice Based on Targeted Plasmonic Hyperthermia
Ribera, J., Vilches, C., Sanz, V., de Miguel, I., Portolés, I., Córdoba‐Jover, B., Prat, E., Nunes, V., Jiménez, W., Quidant, R., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c00988 · Cited by 49
Jang, H., Lee, Y. B., Moon, H., Chung, J., Nam, J. Y., Cho, E. J., Lee, J., Yu, S. J., Kim, Y. J., Lee, J., et al. (2022) · Hepatology · doi:10.1002/hep.32380 · Cited by 48
Self-citationRole of hemostatic factors in hepatic injury and disease: animal models de‐liver
Kopec, A. K., Joshi, N., & Luyendyk, J. P. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13327 · Cited by 47
Effects of aspirin and enoxaparin in a rat model of liver fibrosis
Li, C.-J., Yang, Z., Shi, X., & Liu, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i35.6412 · Cited by 47
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Argenziano, M. E., Kim, M. N., Montori, M., Bucchianico, A. D., Balducci, D., Ahn, S. H., & Svegliati‐Baroni, G. (2024) · Hepatology International · doi:10.1007/s12072-024-10692-4 · Cited by 52
Aspirin in Hepatocellular Carcinoma
Ricciotti, E., Wangensteen, K. J., & FitzGerald, G. A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0758 · Cited by 44
Dong, K., Zheng, Y., Wang, Y., & Guo, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-80801-8 · Cited by 43
Platelets and Platelet‐Derived Extracellular Vesicles in Liver Physiology and Disease
Balaphas, A., Meyer, J., Sadoul, K., Fontana, P., Morel, P., Gonelle‐Gispert, C., & Bühler, L. H. (2019) · Hepatology Communications · doi:10.1002/hep4.1358 · Cited by 43
Till Death Do Us Part—The Multifaceted Role of Platelets in Liver Diseases
Mußbacher, M., Brunnthaler, L., Panhuber, A., Starlinger, P. P., & Assinger, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063113 · Cited by 41
de Zawadzki, A., Leeming, D. J., Sanyal, A. J., Anstee, Q. M., Schattenberg, J. M., Friedman, S. L., Schuppan, D., & Karsdal, M. A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.039 · Cited by 42
Self-citationPeng, Z., Rothweiler, S., Wei, G., Ikenaga, N., Liu, S. B., Sverdlov, D., Vaid, K. A., Longhi, M. S., Kuang, M., Robson, S. C., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1084 · Cited by 40
Self-citationPharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
Liver Fibrosis and Inflammation under the Control of ERK2
Jeng, K., Lu, S.-J., Wang, C.-H., & Chang, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113796 · Cited by 39
Aspirin and the risk of hepatocellular carcinoma development in patients with alcoholic cirrhosis
Shin, S., Lee, S. H., Lee, M., Kim, J. H., Lee, W., Lee, H. W., Park, M. S., Park, S. W., Kim, T. S., & Choi, D. H. (2020) · Medicine · doi:10.1097/md.0000000000019008 · Cited by 37
Minciună, I., Taru, M. G., Procopeț, B., & Ştefănescu, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051406 · Cited by 37
Boccatonda, A., Cane, L. D., Marola, L., D'Ardes, D., Lessiani, G., di Gregorio, N., Ferri, C., Cipollone, F., Serra, C., Santilli, F., et al. (2024) · Life · doi:10.3390/life14040473 · Cited by 35
The Provocative Roles of Platelets in Liver Disease and Cancer
Marie, P. K., Fowlkes, N. W., Afshar‐Kharghan, V., Martch, S. L., Sorokin, A. V., Shen, J. P., Morris, V. K., Dasari, A. N., You, N., Sood, A. K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643815 · Cited by 32
Schwarzkopf, K. M., Bojunga, J., Rüschenbaum, S., Martinez, Y., Mücke, M. M., Seeger, F. H., Schoelzel, F., Zeuzem, S., Friedrich‐Rust, M., & Lange, C. M. (2018) · Hepatology Communications · doi:10.1002/hep4.1254 · Cited by 32
Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications
Airola, C., Pallozzi, M., Cerrito, L., Santopaolo, F., Stella, L., Gasbarrini, A., & Ponziani, F. R. (2023) · Cells · doi:10.3390/cells12131712 · Cited by 33
Haghgoo, S. M., Sharafi, H., & Alavian, S. M. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0357 · Cited by 31
Platelets in Non-alcoholic Fatty Liver Disease
Dalbeni, A., Castelli, M., Zoncapè, M., Minuz, P., & Sacerdoti, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.842636 · Cited by 33
Zhou, J., Deng, Y., Yan, L., Zhao, H., & Wang, G. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.06.004 · Cited by 31
Iqbal, U., Dennis, B. B., Li, A. A., Cholankeril, G. T., Kim, D., Khan, M. A., & Ahmed, A. (2018) · Hepatology International · doi:10.1007/s12072-018-9918-2 · Cited by 31
The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics
Malladi, N., Alam, M. J., Maulik, S. K., & Banerjee, S. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106766 · Cited by 33
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Lee, H. A., Chang, Y. W., Sung, P. S., Yoon, E. L., Lee, H. W., Yoo, J., Lee, Y., An, J., Song, D. S., Cho, Y. Y., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0186 · Cited by 31
Self-citationMyofibroblast specific targeting approaches to improve fibrosis treatment
Beaven, E., Kumar, R., Bhatt, H. N., Esquivel, S. V., & Nurunnabi, M. (2022) · Chemical Communications · doi:10.1039/d2cc04825f · Cited by 30
Gong, J., Han, J., He, J., Liu, J., Han, P., Wang, Y., Li, M., Li, D., Ding, X., Du, Z., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.65 · Cited by 29
Pavlović, N., Kopsida, M., Gerwins, P., & Heindryckx, F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119612 · Cited by 28
Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association?
Kopec, A. K., & Luyendyk, J. P. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1579655 · Cited by 28
Feldbrügge, L., Jiang, Z. G., Csizmadia, E., Mitsuhashi, S., Tran, S., Yee, E. U., Rothweiler, S., Vaid, K. A., Sévigny, J., Schmelzle, M., et al. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9590-3 · Cited by 28
Self-citationSun, Z., Zhao, H., Yang, S., Liu, R., Yi, L., Gao, J., Liu, S., Chen, Y., & Zhang, Z. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.10.309 · Cited by 25
Self-citationProgress in research on the roles of TGR5 receptor in liver diseases
Ma, K., Tang, D., Yu, C. J., & Zhao, L. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1903547 · Cited by 25
Kyritsi, K., Meng, F., Zhou, T., Wu, N., Venter, J. K., Francis, H., Kennedy, L. L., Onori, P., Franchitto, A., Bernuzzi, F., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.03.013 · Cited by 24
The Important Roles of Natural Killer Cells in Liver Fibrosis
Yang, M. J., Vanderwert, E., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051391 · Cited by 22
New and Old Key Players in Liver Cancer
Cuesta, Á. M., Palao, N., Bragado, P., Gutiérrez-Uzquiza, Á., Herrera, B. M., Sánchez, A., & Porrás, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417152 · Cited by 23
Mahmoud, N. I., Messiha, B. A. S., Salehc, I. G., Abo‐Saif, A. A., & Abdel‐Bakky, M. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.078 · Cited by 20
Antiplatelet drugs and liver fibrosis
Czajka, P., Przybyłkowski, A. M., Nowak, A., Postula, M. A., Wolska, M., Mirowska-Guzel, D. M., Członkowska, A., & Eyileten, C. (2021) · Platelets · doi:10.1080/09537104.2021.1883574 · Cited by 19
The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis
Jia, T., Xu, T., Smeets, B., Buhl, E. M., Moeller, M. J., Floege, J., Klinkhammer, B. M., & Boor, P. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022040491 · Cited by 19
Bulboacă, A. E., Porfire, A. S., Rus, V., Nicula, C. A., Bulboacă, C. A., & Bolboaca, S. D. (2022) · Antioxidants · doi:10.3390/antiox11020412 · Cited by 18
Cellular crosstalk during cholestatic liver injury
Thomson, J., Hargrove, L. A., Kennedy, L. L., Demieville, J., & Francis, H. (2017) · Liver Research · doi:10.1016/j.livres.2017.05.002 · Cited by 17
Stellate Cells and Hepatic Fibrosis
Hasegawa, D., Wallace, M. C., & Friedman, S. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00004-x · Cited by 17
Yang, Y., Wang, L., Yan, L., Zhang, L., Zhou, W., Chen, Q., Chen, Y., Zheng, S., Duan, Z., & Li, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8703 · Cited by 17
Hou-Gang, L., You, P., Xia, Y., Cai, Y., Tu, Y., Wang, M., Song, W., Quan, T.-M., Ren, H.-Y., Yan-wen, L., et al. (2020) · Current Medical Science · doi:10.1007/s11596-020-2211-3 · Cited by 16
Tan, J. L., Sidhu-Brar, S., Woodman, R. J., & Chinnaratha, M. A. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00842-y · Cited by 15
Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis
Giuli, L., Pallozzi, M., Venturini, G., Gasbarrini, A., Ponziani, F. R., & Santopaolo, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612754 · Cited by 17
Crosstalk in extrahepatic and hepatic system in NAFLD / NASH
Duan, Y., Yang, Y. Z., Zhao, S., Bai, Y., Yao, W., Gao, X., & Yin, J. (2024) · Liver International · doi:10.1111/liv.15967 · Cited by 16
Thongtan, T., Deb, A., Vutthikraivit, W., Laoveeravat, P., Mingbunjerdsuk, T., Islam, S. R., & Islam, E. A. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01230-3 · Cited by 15
Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma
Simon, T. G., & Chan, A. T. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.06.002 · Cited by 15
Joshi, N., Kopec, A. K., Ray, J. L., & Luyendyk, J. P. (2016) · Toxicology · doi:10.1016/j.tox.2016.07.021 · Cited by 14
Liu, F., Zeng, J., Zhu, D., Zhang, R., Xu, X., Wang, M., Zhang, Y., Xia, H., & Feng, Z. (2017) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22342 · Cited by 14
Platelets: A review of their function and effects in liver diseases
Chen, H., Chen, X., & Wang, G. (2020) · Liver Research · doi:10.1016/j.livres.2020.08.002 · Cited by 13
Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development
Sánchez, P. S., Rigual, M. D. M., & Djouder, N. (2021) · Cancers · doi:10.3390/cancers13205045 · Cited by 13
da Silva, C. M., Ferrari, G. D., Alberici, L. C., Malaspina, O., & Moraes, K. C. M. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03717-7 · Cited by 13
Yang, Y., Li, W., Liu, C., Liu, J., Yang, L., Yue, W., Yang, L., Xue, R., Zhang, K., Zhang, H., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166754 · Cited by 12
Ipsen, D. H., Skat‐Rørdam, J., Svenningsen, M., Andersen, M. V., Latta, M. R., Buelund, L. E., Lintrup, K., Skaarup, R., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13549 · Cited by 12
Jin, J., Cheng, K., Chen, M., Liang, H., & Zhang, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.117394 · Cited by 13
Metadata
- Authors
- Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., Schuppan, D., & Popov, Y.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Pfizer (United States) (US)
- Corresponding author
- Popov, Yury
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 147
- Issue
- 6
- Pages
- 1378-1392
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2121815683
- Cited by
- 164
- References
- 36
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 13 · 2023: 15 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 5 · 2017: 21 · 2016: 10 · 2015: 8 · 2014: 1
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Tokyo Women's Medical University
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- platelet-derived growth factor beta, hepatic stellate cell activation, biliary fibrosis, liver fibrosis, platelets, low-dose aspirin, platelet depletion, CD41, alpha-smooth muscle actin, collagen deposition, fibrosis biomarkers
- MeSH terms
- ATP-Binding Cassette Sub-Family B Member 4, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Aspirin, Blood Platelets, Disease Models, Animal, Female, Humans, Liver Cirrhosis, Male, Mice, Inbred C57BL, Middle Aged, Platelet Aggregation Inhibitors, RNA, Messenger, Bile Ducts, Extrahepatic, Mice, Knockout, ATP Binding Cassette Transporter, Subfamily B, Proto-Oncogene Proteins c-sis, Hepatic Stellate Cells, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
